Drug intelligence / Profile preview

lactobacillus johnsonii NSP009

Development stage
Preclinical
Modality
Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral
01

Overview

*Lactobacillus johnsonii NSP009* is a specific strain of the probiotic species *Lactobacillus johnsonii*, a Gram-positive lactic acid bacterium that naturally inhabits the human and animal gastrointestinal tract[1][10]. This NSP009 strain is used experimentally and in dietary supplements for its health-promoting properties, particularly for gut health and immunomodulation[5][9]. It acts primarily by producing lactic acid and hydrogen peroxide, which help inhibit pathogenic bacteria, modulate immune responses, enhance epithelial barrier function, and may mitigate inflammation and infection[1][2][5]. NSP009, as studied in synbiotic formulations, has shown synergistic effects with β-glucan in ameliorating colitis by regulating gut microbiota and maintaining intestinal barrier homeostasis[5][9]. Its mechanism of action involves antimicrobial activity via acidification and H₂O₂ production, competitive inhibition of pathogens such as *Helicobacter pylori*, and supporting gut mucosal integrity[1][2][3][5]. The strain is under investigation as part of dietary supplements and functional foods for digestive tract pathologies, with translational potential into precision medicine in gastrointestinal diseases[2][5].

Brand names
lactobacillus johnsonii NSP009
Other names
L. johnsonii NSP009
02

Targets

JAM2 (Junctional adhesion molecule B)AHR (Aryl hydrocarbon receptor)

Beyond the preview

Go deeper on lactobacillus johnsonii NSP009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus johnsonii NSP009.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call